Skip to main content
SpringerLink
Log in

Interferon-γ-Release-Assays in der Tuberkulosediagnostik

Interferon-γ release assays in tuberculosis diagnostics

  • Schwerpunkt: Lunge und Infektionen
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Seit 2 Jahren stehen mit dem QuantiFERON®-TB Gold In-Tube und dem T-SPOT®-TB CE-markierte Interferon-γ-Release-Assays (IGRA) für die Tuberkulosediagnostik zur Verfügung. Seither gibt es eine Vielzahl von Studien, die die Tests analysieren. Für England, die USA und die Schweiz wurden von nationalen Fachgremien Leitlinien für den diagnostischen Einsatz der IGRA publiziert. Diagnostik und Management der Tuberkulose können aber von Land zu Land entschieden abweichen. Die vorliegende Übersicht soll eine praxisnahe Hilfestellung für Indikation, Präanalytik und Befundinterpretation der IGRA bei verschiedenen klinischen Konstellationen geben. Sie bindet die IGRA in bestehende Leitlinien zum Tuberkulosemanagement ein.

Abstract

Two years ago, CE certified interferon-γ release assays (IGRA) were launched on the German market (QuantiFERON®-TB Gold In-Tube and T-SPOT®-TB). Since this time, a multitude of studies have analysed these assays. Guidelines have been elaborated by national expert committees of England, the USA and Switzerland. However, standards of tuberculosis diagnostics and management may vary from country to country. This statement provides practice relevant recommendations for indications, pre-analytics and the interpretation of IGRA test results under different clinical conditions. The IGRA are integrated into existing guidelines for the management of tuberculosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Anonymous (1995) Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep 44: 19–34

    PubMed  Google Scholar 

  2. Anonymous (2000) American Thoracic Society: Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 49: 1–51

    Google Scholar 

  3. Anonymous (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 161: S221–S247

    PubMed  Google Scholar 

  4. Arend SM, Thijsen SF, Leyten EM et al. (2006) Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med; Epub ahead of print

  5. Barnes PF (2006) Weighing gold or counting spots: which is more sensitive to diagnose latent tuberculosis infection? Am J Respir Crit Care Med 174: 731–732

    Article  PubMed  Google Scholar 

  6. Berufsgenossenschaften (Hrsg) (1998) Arbeitsmedizinische Vorsorge. Berufsgenossenschaftliche Grundsätze für arbeitsmedizinische Vorsorgeuntersuchungen (2. Aufl.). Gentner, Stuttgart

  7. Biostoffverordnung (1999) Verordnung zur Umsetzung von EG-Richtlinien über den Schutz der Beschäftigten gegen Gefährdung durch biologische Arbeitsstoffe bei der Arbeit (BioStoffV) vom 27.01.1999. Bundesgesetzblatt I: 50–60

    Google Scholar 

  8. Britton WJ, Gilbert GL, Wheatley J et al. (2005) Sensitivity of human gamma interferon assay and tuberculin skin testing for detecting infection with Mycobacterium tuberculosis in patients with culture positive tuberculosis. Tuberculosis (Edinb) 85: 137–145

    Google Scholar 

  9. Brodhun B, Gronauer W, Haas W et al. (2005) Empfehlungen zur Tuberkulose-Umgebungsuntersuchung für die Gesundheitsämter Bayerns. 1. Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, Erlangen, http://www.lgl.bayern.de

  10. Brodin P, Rosenkrands I, Andersen P et al. (2004) ESAT-6 proteins: protective antigens and virulence factors? Trends Microbiol 12: 500–508

    Article  PubMed  Google Scholar 

  11. Brosch R, Gordon SV, Marmiesse M et al. (2002) A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 99: 3684–3689

    Article  PubMed  Google Scholar 

  12. Burmester G-R, Detert J (2003) Neue Therapien in der Behandlung der rheumatoiden Arthritis. Arztinformation Oktober/Dezember 2003. http://www.dgrh.de/572.html

  13. Chapman AL, Munkanta M, Wilkinson KA et al. (2002) Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 16: 2285–2293

    Article  PubMed  Google Scholar 

  14. Dalhoff K, Ewig S, Hoffken G et al. (2002) [Recommendations for the diagnosis, therapy and prevention of pneumonia in the immunocompromised host]. Pneumologie 56: 807–831

    Article  PubMed  Google Scholar 

  15. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (1996) Richtlinien zur Tuberkulindiagnostik. Dtsch Ärztebl 93/18: 1199–1201

    Google Scholar 

  16. Dewan PK, Grinsdale J, Kawamura LM (2007) Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis 44: 69–73

    Article  PubMed  Google Scholar 

  17. Dheda K, Lalvani A, Miller RF et al. (2005) Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 19: 2038–2041

    PubMed  Google Scholar 

  18. Diel R, Nienhaus A, Lange C et al. (2006) Cost optimization of screening for latent tuberculosis in close contacts. Eur Respir J 28: 35–44

    Article  PubMed  Google Scholar 

  19. Ewer K, Deeks J, Alvarez L et al. (2003) Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361: 1168–1173

    Article  PubMed  Google Scholar 

  20. Ferrand RA, Bothamley GH, Whelan A et al. (2005) Interferon-gamma responses to ESAT-6 in tuberculosis patients early into and after anti-tuberculosis treatment. Int J Tuberc Lung Dis 9: 1034–1039

    PubMed  Google Scholar 

  21. Ferrara G, Losi M, D’Amico R et al. (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367: 1328–1334

    Article  PubMed  Google Scholar 

  22. Goletti D, Carrara S, Vincenti D et al. (2006) Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. Clin Microbiol Infect 12: 544–550

    Article  PubMed  Google Scholar 

  23. Hauer B (2006) Diagnostik der Tuberkuloseinfektion: Tuberkulintest und Gamma-Interferontest. Pneumologe 3: 277–286

    Article  Google Scholar 

  24. Hauer B, Loddenkemper R, Detjen A et al. (2006) [Interferon-gamma assays – description and assessment of a new tool in the diagnosis of tuberculosis]. Pneumologie 60: 29–44

    Article  PubMed  Google Scholar 

  25. Hill PC, Brookes RH, Fox A et al. (2004) Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 38: 966–973

    Article  PubMed  Google Scholar 

  26. Johnson PD, Stuart RL, Grayson ML et al. (1999) Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol 6: 934–937

    PubMed  Google Scholar 

  27. Kang YA, Lee HW, Yoon HI et al. (2005) Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 293: 2756–2761

    Article  PubMed  Google Scholar 

  28. Keane J, Gershon S, Wise RP et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098–1104

    Article  PubMed  Google Scholar 

  29. Kobashi Y, Obase Y, Fukuda M et al. (2006) Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis 43: 1540–1546

    Article  PubMed  Google Scholar 

  30. Kollecker S (2003) Zur Frage der Anzeigepflicht von Ärzten bei Tuberkulinkonversion. In: Nienhaus A, Brandenburg S, Teschler H (Hrsg) Tuberkulose als Berufskrankheit. Ein Leitfaden zur Begutachtung. ecomed, Landsberg, S 68–70

  31. Lalvani A, Pathan AA, Durkan H et al. (2001) Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357: 2017–2021

    Article  PubMed  Google Scholar 

  32. Lalvani A, Pathan AA, McShane H et al. (2001) Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 163: 824–828

    PubMed  Google Scholar 

  33. Liebeschuetz S, Bamber S, Ewer K et al. (2004) Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 364: 2196–2203

    Article  PubMed  Google Scholar 

  34. Mazurek GH, Jereb J, Lobue P et al. (2005) Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54: 49–55

    PubMed  Google Scholar 

  35. Meier T, Eulenbruch HP, Wrighton-Smith P et al. (2005) Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis 24: 529–536

    Article  PubMed  Google Scholar 

  36. Mohan AK, Cote TR, Block JA et al. (2004) Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39: 295–299

    Article  PubMed  Google Scholar 

  37. Mori T, Sakatani M, Yamagishi F et al. (2004) Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 170: 59–64

    Article  PubMed  Google Scholar 

  38. NICE (Ed) (2006) Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Royal College of Physicians, London

  39. Nienhaus A, Remé T (2003) Zur Frage der Anzeigepflicht von Ärzten bei Tuberkulinkonversion. In: Nienhaus A, Brandenburg S, Teschler H (Hrsg) Tuberkulose als Berufskrankheit. Ein Leitfaden zur Begutachtung. ecomed, Landsberg, S 174–178

  40. Nienhaus A, Loddenkemper R, Hauer B et al. (in press) Tuberkuloseinfektion im Gesundheitswesen – Evaluation des Interferon-gamma Release Assays. Pneumologie

  41. Pai M, Riley LW, Colford JMJ (2004) Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 4: 761–776

    Article  PubMed  Google Scholar 

  42. Pai M, Gokhale K, Joshi R et al. (2005) Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 293: 2746–2755

    Article  PubMed  Google Scholar 

  43. Pai M, Kalantri S, Dheda K (2006) New tools and emerging technologies for the diagnosis of tuberculosis. Part I: Latent tuberculosis. Expert Rev Mol Diagn 6: 413–422

    Article  PubMed  Google Scholar 

  44. Piana F, Codecasa LR, Besozzi G et al. (2006) Use of commercial interferon-gamma assays in immunocompromised patients for tuberculosis diagnosis. Am J Respir Crit Care Med 173: 130; author reply 130–131

    PubMed  Google Scholar 

  45. Piana F, Codecasa LR, Cavallerio P et al. (2006) Use of a T-cell based test for detection of TB infection among immunocompromised patients. Eur Respir J 28: 31–34

    Article  PubMed  Google Scholar 

  46. Richeldi L, Ewer K, Losi M et al. (2004) T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med 170: 288–295

    Article  PubMed  Google Scholar 

  47. Richeldi L (2006) An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 174: 736–742

    Article  PubMed  Google Scholar 

  48. Schaberg T, Hauer B, Haas WH et al. (2004) [Latent tuberculosis infection: recommendations for preventive therapy in adults in Germany]. Pneumologie 58: 255–270

    Article  PubMed  Google Scholar 

  49. Schablon A, Diel R, Beckmann G et al. (2006) Evaluation des Tbc-Bluttests in der betrieblichen Praxis. http://www.bgw-online.de

  50. Shams H, Weis SE, Klucar P et al. (2005) Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 172: 1161–1168

    Article  PubMed  Google Scholar 

  51. Stuart RL, Olden D, Johnson PD et al. (2000) Effect of anti-tuberculosis treatment on the tuberculin interferon-gamma response in tuberculin skin test (TST) positive health care workers and patients with tuberculosis. Int J Tuberc Lung Dis 4: 555–561

    PubMed  Google Scholar 

  52. Wang L, Turner MO, Elwood RK et al. (2002) A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 57: 804–809

    Article  PubMed  Google Scholar 

  53. Wrighton-Smith P, Zellweger JP (2006) Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 28: 45–50

    Article  PubMed  Google Scholar 

  54. Yew WW, Leung CC (2006) Update in tuberculosis 2005. Am J Respir Crit Care Med 173: 491–498

    Google Scholar 

Download references

Danksagung

Wir danken sehr herzlich Frau Elvira Richter, Forschungszentrum Borstel, Herrn Albert Neher, Asklepios-Fachkliniken München-Gauting, Frau Martina Sester, Klinik für Nephrologie, Universität Homburg an der Saar, und Herrn Harald Mauch für die engagierte Hilfe bei der Erstellung des Manuskripts und die vielen entscheidenden Verbesserungen, die sie bei seiner Entstehung eingebracht haben.

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Arbeitskreis Mykobakterien (AKM),Institut für Mikrobiologie und Labordiagnostik (IML), Asklepios Fachkliniken München-Gauting, Robert-Koch-Allee 2, 82131, Gauting, Deutschland

    H. Hoffmann

  2. Gesundheitsamt, Landratsamt Würzburg, Würzburg, Deutschland

    G. Loytved

  3. Arbeitskreis Mykobakterien (AKM), Institut für Infektionskrankheiten der Universität Bern, Bern, Schweiz

    T. Bodmer

Authors
  1. H. Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Loytved
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Bodmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Hoffmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoffmann, H., Loytved, G. & Bodmer, T. Interferon-γ-Release-Assays in der Tuberkulosediagnostik. Internist 48, 497–506 (2007). https://doi.org/10.1007/s00108-007-1827-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-007-1827-8

Schlüsselwörter

Keywords

Search

Navigation